UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No.4 and Amendment No.6)*
QUESTCOR PHARMACEUTICALS INC.
- -------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- -------------------------------------------------------------------------------
(Title of Class of Securities)
232808105
- -------------------------------------------------------------------------------
(CUSIP Number)
Joseph J. Giunta, Esq.
Skadden, Arps, Slate, Meagher & Flom LLP
300 South Grand Avenue
Los Angeles, CA 90071
(213) 687-5000
- -------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
March 10, 2003
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-(1)(g), check the
following box .
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13D
- -------------------------------------------------------------------------------
CUSIP No. 232808105
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Claudio Cavazza
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)[X]
(b)[ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Italy
- -------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES ----------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 16,461,375
EACH
REPORTING ----------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER
2,656,781
----------------------------------------------
10 SHARED DISPOSITIVE POWER
10,698,712
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
16,461,375
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [ ]
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
38.73%
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
- -------------------------------------------------------------------------------
SCHEDULE 13D
- -------------------------------------------------------------------------------
CUSIP No. 232808105
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Paolo Cavazza
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [X]
(b) [ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Italy
- -------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES ----------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 16,461,375
EACH
REPORTING ----------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER
2,656,782
----------------------------------------------
10 SHARED DISPOSITIVE POWER
11,147,812
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
16,461,375
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [ ]
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
38.73%
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
IN
- -------------------------------------------------------------------------------
SCHEDULE 13D
- -------------------------------------------------------------------------------
CUSIP No. 232808105
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Sigma-Tau Finanziaria SpA
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [X]
(b) [ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Italy
- -------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES ----------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 16,461,375
EACH
REPORTING ----------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
----------------------------------------------
10 SHARED DISPOSITIVE POWER
10,698,712
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
16,461,375
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [ ]
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
38.73%
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
- -------------------------------------------------------------------------------
SCHEDULE 13D
- -------------------------------------------------------------------------------
CUSIP No. 232808105
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Sigma-Tau International S.A.
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [X]
(b) [ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Luxembourg
- -------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES ----------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 16,461,375
EACH
REPORTING ----------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
----------------------------------------------
10 SHARED DISPOSITIVE POWER
10,698,712
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
16,461,375
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [ ]
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
38.73%
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
- -------------------------------------------------------------------------------
SCHEDULE 13D
- -------------------------------------------------------------------------------
CUSIP No. 232808105
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
Defiante Farmaceutica L.D.A.
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [X]
(b) [ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 SOURCE OF FUNDS
- -------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(e) [ ]
- -------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Portugal
- -------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 0
SHARES ----------------------------------------------
BENEFICIALLY 8 SHARED VOTING POWER
OWNED BY 16,461,375
EACH
REPORTING ----------------------------------------------
PERSON WITH 9 SOLE DISPOSITIVE POWER
0
----------------------------------------------
10 SHARED DISPOSITIVE POWER
2,025,315
- -------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
16,461,375
- -------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [ ]
- -------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
38.73%
- -------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
- -------------------------------------------------------------------------------
Amendment No. 4 and
Amendment No. 6 to
Statement on Schedule 13D
This Amendment No. 4 (the "Amendment No. 4") amends the Statement on
Schedule 13D filed with the Securities and Exchange Commission ("SEC") on March
25, 2002 (the "Sigma/Defiante Schedule 13D"), as amended, relating to shares of
the common stock, no par value (the "Common Stock"), of Questcor Pharmaceuticals
Inc., a California corporation ("Questcor"). This Amendment No. 6 (the
"Amendment No. 6" and, together with the Amendment No. 4, this "Statement")
amends the Statement on Schedule 13D, filed with the SEC on August 7, 2001 (the
"Cavazza/Sigma Schedule 13D" and, together with the Sigma/Defiante Schedule 13D,
the "Schedule 13Ds"), as amended, relating to the shares of Common Stock.
Pursuant to Rule 13d-2 of Regulation 13D-G promulgated under the Securities
Exchange Act of 1934, as amended (the "Act"), this Amendment No. 4 is being
filed on behalf of Sigma-Tau Finanziaria SpA, an Italian corporation ("Sigma
Tau") and Defiante Farmaceutica L.D.A., a Portuguese corporation ("Defiante")
(formerly known as Defiante Farmaceutica Unipessoal L.D.A.), and this Amendment
No. 6 is being filed on behalf of Sigma-Tau International S.A., a Luxembourg
corporation ("Sigma Tau International") (formerly known as Sigma-Tau Finance
Holding S.A.), Mr. Claudio Cavazza ("Mr. C. Cavazza") and Mr. Paolo Cavazza
("Mr. P. Cavazza" and, together with Mr. C. Cavazza, Sigma Tau International,
Defiante and Sigma Tau, the "Reporting Persons").
Item 4. Purpose of the Transaction.
Item 4 of the Schedule 13Ds are hereby amended to add the following:
The Reporting Persons originally acquired the shares reported herein to
gain an equity investment interest in Questcor. The Reporting Persons evaluate
on an ongoing basis Questcor's financial condition, business operations and
prospects. Based on such evaluations and prevailing market conditions, the
Reporting Persons are reevaluating their investment in the Questcor, and subject
to compliance with Section 16(b) of the Act, and the rules promulgated
thereunder, have determined to sell all or a portion of the shares reported
herein. Such sales, if they occur, will be through open market transactions or
privately negotiated, and will depend on prevailing market conditions at the
time of sale. The Reporting Persons do not currently intend to commence sales
prior to March 21, 2003.
Except as set forth in this Item 4, the Reporting Persons have no
present plans or proposals that relate to or that would result in any of the
actions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the
Act.
Item 7. Material to be Filed as Exhibits.
EXHIBIT 1 - Joint Filing Agreement dated January 17, 2003 by and
between the Reporting Persons1.
____________________
1 Incorporated by reference to Exhibit 1 of Amendment No. 1 and Amendment No.
3 to the Statement on Schedule 13D, filed with the SEC on January 17, 2003,
relating to the shares of Common Stock.
Signatures
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement with respect to Claudio
Cavazza is true, complete and correct.
Dated: March 11, 2003
CLAUDIO CAVAZZA
By: /s/ CLAUDIO CAVAZZA
-----------------------
Name: Claudio Cavazza
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement with respect to Paolo
Cavazza is true, complete and correct.
Dated: March 11, 2003
PAOLO CAVAZZA
By: /s/ PAOLO CAVAZZA
-----------------------
Name: Paolo Cavazza
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement with respect to
Sigma-Tau Finanziaria SpA is true, complete and correct.
Dated: March 11, 2003
SIGMA-TAU FINANZIARIA SPA
By: /s/ MARIO ARTALI
-------------------------
Name: Mario Artali
Title: Managing Director
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement with respect to
Sigma-Tau International S.A. is true, complete and correct.
Dated: March 11, 2003
SIGMA-TAU INTERNATIONAL S.A.
By: /s/ ANTONIO NICOLAI
-------------------
Name: Antonio Nicolai
Title: Director
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement with respect to
Defiante Farmaceutica L.D.A. is true, complete and correct.
Dated: March 11, 2003
DEFIANTE FARMACEUTICA L.D.A.
By: /s/ RAFFAELE SANGUIGNI
------------------------
Name: Raffaele Sanguigni
Title: Director
The original statement shall be signed by each person on whose behalf
the statement is filed or his authorized representative. If the statement is
signed on behalf of a person by his authorized representative (other than an
executive officer or general partner of the filing person), evidence of the
representative's authority to sign on behalf of such person shall be filed with
the statement: provided, however, that a power of attorney for this purpose
which is already on file with the Commission may be incorporated by reference.
The name and any title of each person who signs the statement shall be typed or
printed beneath his signature.
Attention: Intentional misstatements or omissions of fact constitute Federal
criminal violations (See 18 U.S.C. 1001)